Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic

Molecular Cancer Therapeutics

Volumn 14, Issue 7, 2015, Pages 1625-1636

  Kearns, Jeffrey D ^a   Bukhalid, Raghida ^a   Sevecka, Mark ^a   Tan, Gege ^a   Gerami Moayed, Nastaran ^a   Werner, Shannon L ^a   Kohli, Neeraj ^a   Burenkova, Olga ^a   Sloss, Callum M ^a   King, Anne M ^a   Fitzgerald, Jonathan B ^a   Nielsen, Ulrik B ^a   Wolf, Beni B ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CETUXIMAB; DULIGOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIREGULIN; FUTUXIMAB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN G1 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; MM 151; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; PHOSPHATE BUFFERED SALINE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; EPITOPE; LIGAND; MM-151;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BIOINFORMATICS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; EPITOPES; FEMALE; HUMANS; LIGANDS; MAP KINASE SIGNALING SYSTEM; MICE, SCID; MICROSCOPY, CONFOCAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939619336     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0772     Document Type: Article

References (59)

1. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37 Suppl 4:S3-8.
2. Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 2012;17:31-50.
3. Yarden Y, Pines G. The ERBB network: at last, cancer therapymeets systems biology. Nat Rev Cancer 2012;12:553-63.
4. Dienstmann R, De Dosso S, Felip E, Tabernero J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 2012;6:15-26.
5. Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer P-J, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011;3:584-95.
6. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97.
7. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011;20:472-86.
8. Gerdes CA, Nicolini VG, Herter S, Van Puijenbroek E, Lang S, Roemmele M, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti - EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 2013;19:1126-38.
9. Jones JT, AkitaRW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-31.
10. Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, et al. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 2005;280:8503-12.
11. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003;284:2-13.
12. Sanders JM, Wampole ME, Thakur ML, Wickstrom E. Molecular determinants of epidermal growth factor binding: a molecular dynamics study. PLoS One 2013;8:e54136.
13. Troyer KL, Luetteke NC, Saxon ML, Qiu TH, Xian CJ, Lee DC. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-alpha. Gastroenterology 2001;121:68-78.
14. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999;126:2739-50.
15. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
16. Roepstorff K, Grandal MV, Henriksen L, Knudsen SLJ, Lerdrup M, Grøvdal L, et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009;10:1115-27.
17. Henriksen L, Grandal MV, Knudsen SLJ, van Deurs B, Grøvdal LM. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS One 2013;8:e58148.
18. Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, et al. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 2012;30:107-16.
19. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 2010;5:e12702.
20. Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, et al. Increased TGF-a as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 2013;19:6751-65.
21. Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A. TGF and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. Clin Cancer Res 2014;20:6429-38.
22. Liska D, Chen C-T, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011;17:472-82.
23. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012;7:272-80.
24. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008;14:6963-73.
25. Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A 2012;109:21046-51.
26. Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011;104:488-95.
27. Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, et al. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 2014;110:648-55.
28. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control inmetastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
29. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74.
30. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013;13:49.
31. Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, et al. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013;139:367-78.
32. Han S-W, OhD-Y, Im S, Park SR, Lee K-W, Song HS, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100:298-304.
33. Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JML, Wu Y, et al. Dosedependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 2009;15:2397-405.
34. Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, et al. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced nonsmall cell lung cancer. J Thorac Oncol 2010;5:1939-48.
35. Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Methods Enzymol 2012;502:67-87.
36. Schoeberl B, Eichler-Jonsson C, Gilles ED, Müller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 2002;20:370-5.
37. Resat H, Ewald JA, Dixon DA, Wiley HS. An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophys J 2003;85:730-43.
38. Bairy S, Wong CF. Influence of kinetics of drug binding on EGFR signaling: a comparative study of three EGFR signaling pathway models. Proteins 2011;79:2491-504.
39. Albeck JG, Mills GB, Brugge JS. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol Cell 2013;49:249-61.
40. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V, GilbertD, et al. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal 2010;3:ra90.
41. Yang X-D, Jia X-C, Corvalan JRF, Wang P, Davis CG. Development of ABXEGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
42. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8.
43. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol 2008;68:93-106.
44. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006;12:6517-22.
45. Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, et al. Approval summary: cetuximab in combination with Cisplatin or Carboplatin and 5-Fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist 2013;18:460-6.
46. Argiles G, Dienstmann R, Elez E, Tabernero J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol 2012;8:373-89.
47. Broadbridge VT, Karapetis CS, Price TJ. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther 2012;12:555-65.
48. Katoh Y, Katoh M. Canonical WNT signaling pathway and human AREG. Int J Mol Med 2006;17:1163-6.
49. Oliveras-Ferraros C, Cufí S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, et al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer 2012;106:1406-14.
50. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-66.
51. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A 2009;106:3294-9.
52. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, et al. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 2010;107:13252-7.
53. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad SciUS A 2005;102:1915-20.
54. DechantM, Weisner W, Berger S, PeippM, Beyer T, Schneider-Merck T, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008;68:4998-5003.
55. Fogler WE, Klinger MR, Abraham KG, Gottlinger HG, Riethmuller G, Daddona PE. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen. Cancer Res 1988;48:6303-8.
56. Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer 1998;78:478-83.
57. Wong DJL, Hurvitz SA. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med 2014;2:1-14.
58. Pedersen MW, Jacobsen HJ, Koefoed K, Dahlman A, Kjaer I, Poulsen TT, et al. Targeting three distinct HER2 domains with a recombinant antibody mixture overcomes trastuzumab resistance. Mol Cancer Ther 2015;14:669-80.
59. Lieu CH, Beeram M, Harb WA, Kearns JD, Sloss CM, Nering R, et al. Safety, pharmacology, and preliminary clinical activity of MM-151: an oligocolnal anti-EGFR therapeutic in patients with cetuximab-resistant CRC and other refractory solid tumors. J Clin Oncol 2015;33 Suppl 3: abst 647.